Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide

Immunology

Volumn 117, Issue 1, 2006, Pages 47-58

  Kikuchi, Takeshi ^a,b   Uehara, Shuichiro ^a,b   Ariga, Haruyuki ^a,c   Tokunaga, Takeshi ^a   Kariyone, Ai ^a   Tamura, Toshiki ^a   Takatsu, Kiyoshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NIHON UNIVERSITY   (Japan)

^c KYORIN UNIVERSITY   (Japan)

Author keywords

Antigen presentation; Cytotoxic T cells; Peptide; T helper 1 cells; Tumour immunity

Indexed keywords

GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; PEPTIDE 18; PEPTIDE 25; PEPTIDE 9; PEPTIDE DERIVATIVE; PROTEIN; SERYLISOLEUCYLISOLEUCYLASPARAGYLPHENYLALANYLGLUTAMINYLLYSINE; TUMOR ANTIGEN; TYROSINE RELATED PROTEIN 2; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTIGEN 85A, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL ANTIGEN; CANCER VACCINE; EPITOPE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; IMMUNE RESPONSE; LYMPHOCYTOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; T CELL DEPLETION; TH1 CELL; THYMOMA; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR RESISTANCE; TUMOR VOLUME; ANIMAL; ANTIGEN PRESENTATION; C57BL MOUSE; CANCER TRANSPLANTATION; CELL CULTURE; CYTOTOXICITY; HELPER CELL; IMMUNIZATION; IMMUNOLOGY; TRANSGENIC MOUSE;

ACYLTRANSFERASES; ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, BACTERIAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; IMMUNIZATION; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; OVALBUMIN; T-LYMPHOCYTES, HELPER-INDUCER; THYMOMA; THYMUS NEOPLASMS;

EID: 33644822063     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2005.02262.x     Document Type: Article

References (45)

1. Boon T Cerottini JC Van den Eynde B Van der Bruggen P Van Pel A Tumor antigens recognized by T lymphocytes Annu Rev Immunol 1994 12 337 65
2. + T cells in antitumor immunity Trends Immunol 2001 22 269 76
3. Davis ID Jefford M Parente P Cebon J Rational approaches to human cancer immunotherapy J Leukoc Biol 2003 73 3 29
4. Wagner H Pfizenmaier K Rollinghoff M The role of the major histocompatibility gene complex in murine cytotoxic T cell responses Adv Cancer Res 1980 31 77 124
5. North RJ The murine antitumor immune response and its therapeutic manipulation Adv Immunol 1984 35 89 155
6. Greenberg PD Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells Adv Immunol 1991 49 281 355
7. Melief CJ Tumor eradication by adoptive transfer of cytotoxic T lymphocytes Adv Cancer Res 1992 58 143 75
8. Rosenberg SA A new era for cancer immunotherapy based on the genes that encode cancer antigens Immunity 1999 10 281 7
9. Finn OJ Cancer vaccines: between the idea and the reality Nat Rev Immunol 2003 3 630 41
10. + T cell responses in antitumor immunity Curr Opin Immunol 1998 10 588 94
11. Rosenberg SA Progress in human tumour immunology and immunotherapy Nature 2001 411 380 4
12. Toes RE Ossendorp F Offringa R Melief CJ CD4 T cells and their role in antitumor immune responses J Exp Med 1999 189 753 6
13. Nishikawa H Tanida K Ikeda H et al. Role of SEREX-defined immunogenic wild-type cellular molecules in the development of tumor-specific immunity Proc Natl Acad Sci USA 2001 98 14571 6
14. Sahin U Tureci O Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host Proc Natl Acad Sci USA 1995 92 11810 13
15. Sahin U Tureci O Pfreundschuh M Serological identification of human tumor antigens Curr Opin Immunol 1997 9 709 16
16. Old LJ Chen YT New paths in human cancer serology J Exp Med 1998 187 1163 7
17. Takatsu K Hamaoka T Tominaga A Kanamasa Y Augmented induction of tumor-specific resistance by priming with Mycobacterium tuberculosis (TBC) and subsequent immunization with PPD-coupled syngeneic tumor cells J Immunol 1980 125 2367 73
18. Takatsu K Kikuchi Y Takahashi T Honjo T Matsumoto M Harada N Yamaguchi N Tominaga A Interleukin 5, a T-cell-derived B-cell differentiation factor also induces cytotoxic T lymphocytes Proc Natl Acad Sci USA 1987 84 4234 8
19. Hamaoka T Takatsu K Okuno K Tsuchida T Functional characterization of the killer-helper factor responsible for the induction of cytotoxic T lymphocytes from thymocytes, and evidence for the nature of this factor as distinct from T cell-replacing factor (TRF) in regard to B cell triggering J Immunol 1981 126 659 65
20. + helper T cell epitopes on mycobacterial antigen in mouse primed with Mycobacterium tuberculosis Int Immunol 1997 9 227 37
21. + Th1 cells Infect Immun 1999 67 4312 19
22. Kariyone A Tamura T Kano H Iwakura Y Takeda K Akira S Takatsu K Immunogenicity of Peptide-25 of Ag85B in Th1 development: role of IFN-γ Int Immunol 2003 15 1183 94
23. Takatsu K Kariyone A The immunogenic peptide for Th1 development Int Immunopharmacol 2003 3 783 800
24. + T helper phenotype development in a T cell receptor transgenic model Int Immunol 2004 16 1691 9
25. -/- mice. Role for IFN-γ in activating apoptosis of hepatocytes J Immunol 1997 159 1418 28
26. Khong HT Rosenberg SA Pre-existing immunity to tyrosinase-related protein (TRP) -2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy J Immunol 2002 168 951 6
27. Horikawa K Kaku H Nakajima H et al. Essential role of Stat5 for IL-5-dependent IgH switch recombination in mouse B cells J Immunol 2001 167 5018 26
28. + T cell help J Exp Med 1997 186 65 70
29. Keene JA Forman J Helper activity is required for the in vivo generation of cytotoxic T lymphocytes J Exp Med 1982 155 768 82
30. Mitchison NA O'Malley C Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response Eur J Immunol 1987 17 1579 83
31. Schoenberger SP Toes RE van der Voort EI Offringa R Melief CJ T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions Nature 1998 393 480 3
32. + T-helper and a T-killer cell Nature 1998 393 474 8
33. Bennett SR Carbone FR Karamalis F Flavell RA Miller JF Heath WR Help for cytotoxic-T-cell responses is mediated by CD40 signalling Nature 1998 393 478 80
34. Rock KL Gamble S Rothstein L Presentation of exogenous antigen with class I major histocompatibility complex molecules Science 1990 249 918 21
35. Rodriguez A Regnault A Kleijmeer M Ricciardi-Castagnoli P Amigorena S Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells Nat Cell Biol 1999 1 362 8
36. Guermonprez P Saveanu L Kleijmeer M Davoust J Van Endert P Amigorena S ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells Nature 2003 425 397 402
37. Houde M Bertholet S Gagnon E et al. Phagosomes are competent organelles for antigen cross-presentation Nature 2003 425 402 6
38. Imai J Hasegawa H Maruya M Koyasu S Yahara I Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells Int Immunol 2005 17 45 53
39. Nishimura T Iwakabe K Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo J Exp Med 1999 190 617 27
40. Mizushima Y Fujiwara H Takai Y Shearer GM Hamaoka T Genetic control of hapten-reactive helper T-cell responses and its implications for the generation of augmented antitumor cytotoxic responses J Natl Cancer Inst 1985 74 1269 73
41. Rice J Elliott T Buchan S Stevenson FK DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines J Immunol 2001 167 1558 65
42. + T cell-based immunotherapy interferes with liver tumor progression in a transgenic mouse model J Immunol 1998 161 5133 7
43. Casares N Lasarte JJ de Cerio AL Sarobe P Ruiz M Melero I Prieto J Borras-Cuesta F Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity Eur J Immunol 2001 31 1780 9
44. Schuler-Thurner B Schultz ES Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells J Exp Med 2002 195 1279 88
45. Slingluff CL Jr. Yamshchikov G Neese P et al. Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes Clin Cancer Res 2001 7 3012 24